AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Jan 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-01-09

Reporting Person: Quimi Daphne (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-09	Common Stock	S	15000	$9.9301	Disposed	166969	Direct
2020-01-09	Common Stock	M	9822	$2.52	Acquired	176791	Direct
2020-01-09	Common Stock	M	1200	$4.38	Acquired	177991	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-09	Stock Options (right to buy)	$2.52	M	9822	Disposed	2023-06-18	Common Stock (9822)	Direct
2020-01-09	Stock Options (right to buy)	$4.38	M	1200	Disposed	2022-06-04	Common Stock (1200)	Direct

Footnotes

F1: The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.93 to $9.94. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: All of these options were fully vested and exercisable as of January 9, 2020.